{"id":48406,"date":"2022-09-14T23:02:34","date_gmt":"2022-09-14T21:02:34","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/qurient-announces-collaboration-agreement-with-msd-to-evaluate-selective-cdk7-inhibitor-q901-in-combination-with-keytruda-pembrolizumab\/"},"modified":"2022-09-14T23:02:34","modified_gmt":"2022-09-14T21:02:34","slug":"qurient-announces-collaboration-agreement-with-msd-to-evaluate-selective-cdk7-inhibitor-q901-in-combination-with-keytruda-pembrolizumab","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/qurient-announces-collaboration-agreement-with-msd-to-evaluate-selective-cdk7-inhibitor-q901-in-combination-with-keytruda-pembrolizumab\/","title":{"rendered":"Qurient Announces Collaboration Agreement with MSD to Evaluate Selective CDK7 Inhibitor Q901 in Combination With KEYTRUDA\u00ae (pembrolizumab)"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\n<i>Q901 is a novel highly selective CDK7 inhibitor<\/i>\n<\/li>\n<li>\n<i>Q901 is ready for dose escalation study in the U.S. for the treatment of selected advanced solid tumors (NCT<\/i> <i>05394103)<\/i>\n<\/li>\n<li>\n<i>The phase 1\/2 study of Q901 and KEYTRUDA is designed to enroll patients with advanced solid tumors<\/i>\n<\/li>\n<\/ul>\n<p>SEONGNAM-SI, South Korea&#8211;(BUSINESS WIRE)&#8211;<a href=\"https:\/\/twitter.com\/hashtag\/Qurient?src=hash\" target=\"_blank\" rel=\"noopener\">#Qurient<\/a>&#8212;<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.qurient.com%2F&amp;esheet=52902137&amp;newsitemid=20220914005974&amp;lan=en-US&amp;anchor=Qurient+Co.+Ltd.&amp;index=1&amp;md5=5ffd8633b63bf764521407df75d863dc\" rel=\"nofollow noopener\" shape=\"rect\">Qurient Co. Ltd.<\/a> (KRX: 115180), a clinical-stage biotech company based in Korea, today announced that the company has entered into a clinical collaboration agreement with MSD (Merck &amp; Co., Inc., Rahway, NJ., USA), for clinical study of <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.qurient.com%2Fbbs%2Fcontent.php%3Fco_id%3Dq702&amp;esheet=52902137&amp;newsitemid=20220914005974&amp;lan=en-US&amp;anchor=Q901&amp;index=2&amp;md5=013d7b66fddb3a4cd696db8f99d18830\" rel=\"nofollow noopener\" shape=\"rect\">Q901<\/a>, a selective CDK7 inhibitor in combination with MSD\u2019s anti-PD-1 therapy KEYTRUDA<sup>\u00ae<\/sup> (pembrolizumab).\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220914005974\/en\/781667\/5\/qurient.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220914005974\/en\/781667\/21\/qurient.jpg\"><\/a><\/p>\n<p>\nUnder this agreement, Qurient will conduct a phase 1\/2 study in the U.S. to evaluate safety and efficacy of Q901 in combination with KEYTRUDA for the treatment of selected advanced solid tumors.\n<\/p>\n<p>\n\u201cWe are pleased to collaborate with MSD to evaluate Q901 in combination with KEYTRUDA for advanced solid tumors where limited treatment options are currently available. Q901 shows very effective tumor growth inhibition through cell cycle regulation and triggers genomic instability, which may set synthetic lethality for anti-PD-1 therapy. The Q901 and anti-PD-1 antibody combination showed beneficial effect in preclinical models, and we expect the same clinical benefits,\u201d said Kiyean Nam, Ph.D., CEO of Qurient. \u201cThe clinical collaboration with MSD on Q901-KEYTRUDA combination follows on clinical collaboration on Q702-KEYTRUDA combination agreement announced in November 2021, and they are important milestones for patients who have had few treatment options, and Qurient\u2019s two lead oncology assets.\u201d\n<\/p>\n<p>\nTerms of the collaboration were not disclosed.\n<\/p>\n<p>\nKEYTRUDA<sup>\u00ae<\/sup> is a registered trademark of Merck Sharp &amp; Dohme, LLC., a subsidiary of Merck &amp; Co., Inc., Rahway, NJ, USA.\n<\/p>\n<p>\n<b>About Q901<\/b>\n<\/p>\n<p>\nQ901 is a highly selective cyclin dependent kinase 7 (CDK7) inhibitor that only inhibits CDK7 in the human kinome. CDK7 is a master regulator of cell cycle checkpoints and an essential component of transcription machinery. Selective inhibition of CDK7 by Q901 specifically kills cancer cells with aberrant cell division cycle or transcriptional regulation. In animal studies, Q901 exerts tumor growth inhibition in a number of murine cell-derived and patient-derived xenograft models, including breast, ovarian, prostate, pancreatic, small-cell lung, and colorectal cancers. Qurient licensed the CDK7 inhibitor program at the discovery research stage from Lead Discovery Center (LDC) and the Max-Planck Society and further optimized the program, completed the IND-enabling studies, and received FDA clearance of investigational new drug (IND) application.\n<\/p>\n<p>\n<b>About Qurient<\/b>\n<\/p>\n<p>\nQurient, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics for oncology and inflammatory diseases from discovery to human proof-of-concept through a virtual R&amp;D project management platform. Qurient\u2019s pipeline includes multiple drug candidates in preclinical to phase 2 clinical developments. For more info, please visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.qurient.com&amp;esheet=52902137&amp;newsitemid=20220914005974&amp;lan=en-US&amp;anchor=www.qurient.com&amp;index=3&amp;md5=1715bcf6b9a84ab7f74f4629a44ed8c5\" rel=\"nofollow noopener\" shape=\"rect\">www.qurient.com<\/a>.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nJessica Yingling, Ph.D., <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.litldog.com%2F&amp;esheet=52902137&amp;newsitemid=20220914005974&amp;lan=en-US&amp;anchor=Little+Dog+Communications+Inc.&amp;index=4&amp;md5=3272f13c436ddefdf217b26ed51fdbef\" rel=\"nofollow noopener\" shape=\"rect\">Little Dog Communications Inc.<\/a>, <a target=\"_blank\" href=\"m&#97;&#x69;&#x6c;t&#111;&#58;&#x6a;&#x65;s&#115;&#x69;&#x63;a&#64;&#108;&#x69;&#x74;l&#100;&#x6f;&#x67;&#46;&#99;&#111;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#x6a;&#x65;&#115;s&#x69;&#x63;&#97;&#64;l&#x69;&#x74;&#108;&#100;o&#x67;&#x2e;&#99;om<\/a>, +1.858.344.8091\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Q901 is a novel highly selective CDK7 inhibitor Q901 is ready for dose escalation study in the U.S. for the treatment of selected advanced solid tumors (NCT 05394103) The phase 1\/2 study of Q901 and KEYTRUDA is designed to enroll patients with advanced solid tumors SEONGNAM-SI, South Korea&#8211;(BUSINESS WIRE)&#8211;#Qurient&#8212;Qurient Co. Ltd. (KRX: 115180), a clinical-stage &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/qurient-announces-collaboration-agreement-with-msd-to-evaluate-selective-cdk7-inhibitor-q901-in-combination-with-keytruda-pembrolizumab\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-48406","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Qurient Announces Collaboration Agreement with MSD to Evaluate Selective CDK7 Inhibitor Q901 in Combination With KEYTRUDA\u00ae (pembrolizumab) - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/qurient-announces-collaboration-agreement-with-msd-to-evaluate-selective-cdk7-inhibitor-q901-in-combination-with-keytruda-pembrolizumab\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Qurient Announces Collaboration Agreement with MSD to Evaluate Selective CDK7 Inhibitor Q901 in Combination With KEYTRUDA\u00ae (pembrolizumab) - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Q901 is a novel highly selective CDK7 inhibitor Q901 is ready for dose escalation study in the U.S. for the treatment of selected advanced solid tumors (NCT 05394103) The phase 1\/2 study of Q901 and KEYTRUDA is designed to enroll patients with advanced solid tumors SEONGNAM-SI, South Korea&#8211;(BUSINESS WIRE)&#8211;#Qurient&#8212;Qurient Co. Ltd. (KRX: 115180), a clinical-stage ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/qurient-announces-collaboration-agreement-with-msd-to-evaluate-selective-cdk7-inhibitor-q901-in-combination-with-keytruda-pembrolizumab\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-14T21:02:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220914005974\/en\/781667\/21\/qurient.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/qurient-announces-collaboration-agreement-with-msd-to-evaluate-selective-cdk7-inhibitor-q901-in-combination-with-keytruda-pembrolizumab\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/qurient-announces-collaboration-agreement-with-msd-to-evaluate-selective-cdk7-inhibitor-q901-in-combination-with-keytruda-pembrolizumab\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Qurient Announces Collaboration Agreement with MSD to Evaluate Selective CDK7 Inhibitor Q901 in Combination With KEYTRUDA\u00ae (pembrolizumab)\",\"datePublished\":\"2022-09-14T21:02:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/qurient-announces-collaboration-agreement-with-msd-to-evaluate-selective-cdk7-inhibitor-q901-in-combination-with-keytruda-pembrolizumab\\\/\"},\"wordCount\":480,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/qurient-announces-collaboration-agreement-with-msd-to-evaluate-selective-cdk7-inhibitor-q901-in-combination-with-keytruda-pembrolizumab\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220914005974\\\/en\\\/781667\\\/21\\\/qurient.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/qurient-announces-collaboration-agreement-with-msd-to-evaluate-selective-cdk7-inhibitor-q901-in-combination-with-keytruda-pembrolizumab\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/qurient-announces-collaboration-agreement-with-msd-to-evaluate-selective-cdk7-inhibitor-q901-in-combination-with-keytruda-pembrolizumab\\\/\",\"name\":\"Qurient Announces Collaboration Agreement with MSD to Evaluate Selective CDK7 Inhibitor Q901 in Combination With KEYTRUDA\u00ae (pembrolizumab) - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/qurient-announces-collaboration-agreement-with-msd-to-evaluate-selective-cdk7-inhibitor-q901-in-combination-with-keytruda-pembrolizumab\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/qurient-announces-collaboration-agreement-with-msd-to-evaluate-selective-cdk7-inhibitor-q901-in-combination-with-keytruda-pembrolizumab\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220914005974\\\/en\\\/781667\\\/21\\\/qurient.jpg\",\"datePublished\":\"2022-09-14T21:02:34+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/qurient-announces-collaboration-agreement-with-msd-to-evaluate-selective-cdk7-inhibitor-q901-in-combination-with-keytruda-pembrolizumab\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/qurient-announces-collaboration-agreement-with-msd-to-evaluate-selective-cdk7-inhibitor-q901-in-combination-with-keytruda-pembrolizumab\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/qurient-announces-collaboration-agreement-with-msd-to-evaluate-selective-cdk7-inhibitor-q901-in-combination-with-keytruda-pembrolizumab\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220914005974\\\/en\\\/781667\\\/21\\\/qurient.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220914005974\\\/en\\\/781667\\\/21\\\/qurient.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/qurient-announces-collaboration-agreement-with-msd-to-evaluate-selective-cdk7-inhibitor-q901-in-combination-with-keytruda-pembrolizumab\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Qurient Announces Collaboration Agreement with MSD to Evaluate Selective CDK7 Inhibitor Q901 in Combination With KEYTRUDA\u00ae (pembrolizumab)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Qurient Announces Collaboration Agreement with MSD to Evaluate Selective CDK7 Inhibitor Q901 in Combination With KEYTRUDA\u00ae (pembrolizumab) - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/qurient-announces-collaboration-agreement-with-msd-to-evaluate-selective-cdk7-inhibitor-q901-in-combination-with-keytruda-pembrolizumab\/","og_locale":"en_US","og_type":"article","og_title":"Qurient Announces Collaboration Agreement with MSD to Evaluate Selective CDK7 Inhibitor Q901 in Combination With KEYTRUDA\u00ae (pembrolizumab) - Pharma Trend","og_description":"Q901 is a novel highly selective CDK7 inhibitor Q901 is ready for dose escalation study in the U.S. for the treatment of selected advanced solid tumors (NCT 05394103) The phase 1\/2 study of Q901 and KEYTRUDA is designed to enroll patients with advanced solid tumors SEONGNAM-SI, South Korea&#8211;(BUSINESS WIRE)&#8211;#Qurient&#8212;Qurient Co. Ltd. (KRX: 115180), a clinical-stage ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/qurient-announces-collaboration-agreement-with-msd-to-evaluate-selective-cdk7-inhibitor-q901-in-combination-with-keytruda-pembrolizumab\/","og_site_name":"Pharma Trend","article_published_time":"2022-09-14T21:02:34+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220914005974\/en\/781667\/21\/qurient.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/qurient-announces-collaboration-agreement-with-msd-to-evaluate-selective-cdk7-inhibitor-q901-in-combination-with-keytruda-pembrolizumab\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/qurient-announces-collaboration-agreement-with-msd-to-evaluate-selective-cdk7-inhibitor-q901-in-combination-with-keytruda-pembrolizumab\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Qurient Announces Collaboration Agreement with MSD to Evaluate Selective CDK7 Inhibitor Q901 in Combination With KEYTRUDA\u00ae (pembrolizumab)","datePublished":"2022-09-14T21:02:34+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/qurient-announces-collaboration-agreement-with-msd-to-evaluate-selective-cdk7-inhibitor-q901-in-combination-with-keytruda-pembrolizumab\/"},"wordCount":480,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/qurient-announces-collaboration-agreement-with-msd-to-evaluate-selective-cdk7-inhibitor-q901-in-combination-with-keytruda-pembrolizumab\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220914005974\/en\/781667\/21\/qurient.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/qurient-announces-collaboration-agreement-with-msd-to-evaluate-selective-cdk7-inhibitor-q901-in-combination-with-keytruda-pembrolizumab\/","url":"https:\/\/pharma-trend.com\/en\/qurient-announces-collaboration-agreement-with-msd-to-evaluate-selective-cdk7-inhibitor-q901-in-combination-with-keytruda-pembrolizumab\/","name":"Qurient Announces Collaboration Agreement with MSD to Evaluate Selective CDK7 Inhibitor Q901 in Combination With KEYTRUDA\u00ae (pembrolizumab) - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/qurient-announces-collaboration-agreement-with-msd-to-evaluate-selective-cdk7-inhibitor-q901-in-combination-with-keytruda-pembrolizumab\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/qurient-announces-collaboration-agreement-with-msd-to-evaluate-selective-cdk7-inhibitor-q901-in-combination-with-keytruda-pembrolizumab\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220914005974\/en\/781667\/21\/qurient.jpg","datePublished":"2022-09-14T21:02:34+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/qurient-announces-collaboration-agreement-with-msd-to-evaluate-selective-cdk7-inhibitor-q901-in-combination-with-keytruda-pembrolizumab\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/qurient-announces-collaboration-agreement-with-msd-to-evaluate-selective-cdk7-inhibitor-q901-in-combination-with-keytruda-pembrolizumab\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/qurient-announces-collaboration-agreement-with-msd-to-evaluate-selective-cdk7-inhibitor-q901-in-combination-with-keytruda-pembrolizumab\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220914005974\/en\/781667\/21\/qurient.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220914005974\/en\/781667\/21\/qurient.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/qurient-announces-collaboration-agreement-with-msd-to-evaluate-selective-cdk7-inhibitor-q901-in-combination-with-keytruda-pembrolizumab\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Qurient Announces Collaboration Agreement with MSD to Evaluate Selective CDK7 Inhibitor Q901 in Combination With KEYTRUDA\u00ae (pembrolizumab)"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48406","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=48406"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48406\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=48406"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=48406"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=48406"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}